Verona Pharma plc (VRNA) Financial Statements

Executive TeamFinancials

Verona Pharma financial statements at a glance

Verona Pharma reported revenue of $42.28 million for fiscal year 2024 (ended December 31, 2024). Net income was -$173.42 million, a net margin of 410.2% loss, and diluted earnings per share were -$2.16.

At the end of fiscal year 2024 it had total assets of $474.24 million, total liabilities of $269.68 million and shareholders' equity of $204.56 million, with cash and short-term investments of $399.76 million and total debt of $122.70 million.

Its operations brought in -$122.20 million of cash; capital spending was $580,000, leaving free cash flow of -$122.78 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2024.

VRNA logo

Verona Pharma plc

VRNAUnited Kingdom
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
42.28M
Prev Year: 0
Operating Revenue
42.26M
Prev Year: 0
Net Income from Continuing Operation Net Minority Interest
-173.42M
Prev Year: -54.37M
YoY: -219.0%
Total Unusual Items Excluding Goodwill
-3.82M
Prev Year: 1.87M
YoY: -304.8%
Total Unusual Items
-3.82M
Prev Year: 1.87M
YoY: -304.8%
Normalized EBITDA
-134.71M
Prev Year: -53.03M
YoY: -154.0%
Tax Effect of Unusual Items
-955.5K
Prev Year: 354.5K
YoY: -369.5%
Cost of Revenue
2.58M
Prev Year: 0
Gross Profit
39.70M
Prev Year: 0
Operating Expense
190.72M
Prev Year: 66.47M
YoY: +187.0%
Selling General and Administrative
149.75M
Prev Year: 50.35M
YoY: +197.4%
Research and Development
44.57M
Prev Year: 17.22M
YoY: +158.9%
Other Taxes
-3.60M
Prev Year: -1.10M
YoY: -226.1%
Total Other Finance Cost
-
Operating Income
-151.03M
Prev Year: -66.47M
YoY: -127.2%
Net Non Operating Interest Income Expense
-8.28M
Prev Year: 10.70M
YoY: -177.4%
Non-operating Interest Income
15.26M
Prev Year: 12.76M
YoY: +19.6%
Non-operating Interest Expense
23.54M
Prev Year: 2.06M
YoY: +1044.5%
Other Income Expense
-3.82M
Prev Year: 1.87M
YoY: -304.8%
Gain on Sale of Securities
-169.0K
Prev Year: 1.87M
YoY: -109.1%
Special Income Charges
-3.65M
Prev Year: 0
Other Special Charges
3.65M
Pre-tax Income
-163.13M
Prev Year: -53.90M
YoY: -202.7%
Provision for Income Taxes
10.29M
Prev Year: 474.0K
YoY: +2070.7%
Net Income Common Stockholders
-173.42M
Prev Year: -54.37M
YoY: -219.0%
Net Income
-173.42M
Prev Year: -54.37M
YoY: -219.0%
Net Income Including Non-Controlling Interests
-173.42M
Prev Year: -54.37M
YoY: -219.0%
Net Income from Continuing Operations
-173.42M
Prev Year: -54.37M
YoY: -219.0%
Diluted NI Available to Com Stockholders
-173.42M
Prev Year: -54.37M
YoY: -219.0%
Basic EPS
-2.16
Prev Year: -0.72
YoY: -200.0%
Diluted EPS
-2.16
Prev Year: -0.72
YoY: -200.0%
Weighted Average Shares (basic)
81.54M
Prev Year: 79.27M
YoY: +2.9%
Weighted Average Shares (diluted)
81.54M
Prev Year: 79.27M
YoY: +2.9%
Rent Expense (supplemental)
-
Total Operating Income as Reported
-154.63M
Prev Year: -67.57M
YoY: -128.8%
Total Expenses
193.31M
Prev Year: 66.47M
YoY: +190.8%
Net Income from Continuing and Discontinued Operation
-173.42M
Prev Year: -54.37M
YoY: -219.0%
Normalized Income
-170.55M
Prev Year: -55.88M
YoY: -205.2%
Interest Income
15.26M
Prev Year: 12.76M
YoY: +19.6%
Interest Expense
23.54M
Prev Year: 2.06M
YoY: +1044.5%
Net Interest Income
-8.28M
Prev Year: 10.70M
YoY: -177.4%
EBIT
-139.59M
Prev Year: -51.84M
YoY: -169.3%
EBITDA
-138.53M
Prev Year: -51.16M
YoY: -170.8%
Reconciled Cost of Revenue
2.58M
Prev Year: 0
Reconciled Depreciation
1.06M
Prev Year: 677.0K
YoY: +56.3%
Values in USD

Verona Pharma key figures by fiscal year

FY2024FY2023FY2022FY2021FY2020
Revenue$42.3M$0$458,000$40.0M$0
Gross profit$39.7M$0$112,000$40.0M–
Operating income-$151.0M-$66.5M-$66.1M-$57.7M-$66.0M
Net income-$173.4M-$54.4M-$68.7M-$55.6M-$65.1M
Diluted EPS-$2.16-$0.72-$1.04-$0.96-$2.00
Total assets$474.2M$308.1M$259.5M$186.6M$204.2M
Total liabilities$269.7M$58.8M$29.0M$38.6M$19.4M
Shareholders' equity$204.6M$249.3M$230.5M$148.0M$184.9M
Cash and short-term investments$399.8M$271.8M$227.8M$148.4M$188.0M
Total debt$122.7M$51.3M$10.6M$5.8M$5.9M
Operating cash flow-$122.2M-$50.2M-$59.9M-$33.3M-$45.1M
Capital spending$580,000–$29,000$12,000$82,000
Free cash flow-$122.8M-$50.2M-$59.9M-$33.3M-$45.2M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2013.

Questions and answers

What was Verona Pharma's revenue in fiscal year 2024?

$42.28 million.

How much profit does Verona Pharma make?

Verona Pharma reported net income of -$173.42 million for fiscal year 2024 (410.2% of revenue); operating income was -$151.03 million.

How much cash and debt does Verona Pharma have?

At the end of fiscal year 2024: cash and short-term investments of $399.76 million and total debt of $122.70 million.

What is Verona Pharma's free cash flow?

-$122.78 million in fiscal year 2024 (operating cash flow of -$122.20 million minus capital spending of $580,000).

MoreVerona Pharma stock overviewVerona Pharma executive team
RelatedPharmaceutical Preparation Manufacturing industryManufacturing sectorThemis Medicare (THEMISMED.NS)Zhejiang Jingxin Pharmaceutical (002020.SZ)Pacific Shuanglin Bio-pharmacy (000403.SZ)Chongqing Genrix Biopharmaceutical (688443.SS)Jamjoom Pharmaceuticals Factory (4015.SR)Kilitch Drugs (India) (KILITCH.NS)
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
© 2026 DataPorium. All rights reserved.|About & MethodologyPrivacy PolicyTerms of Use
LinkedInLinkedInXXYouTubeYouTube